Table II.

Information on the gene mutation status.

A, EGFR
Exon	Amino acid change	Nucleotide change	Cases, n (%)
18	G719A	2156G>C	1 (1.28)
	G719S	2155G>A	1 (1.28)
19	E746_A750del	2235–2249del 15	22 (28.2)
	E746_A750del	2236–2250del 15	2 (2.56)
	L747_P753>S	2240–2257del 18	5 (6.41)
	E746_T751>A	2237–2251del 15	1 (1.28)
	E746_T751>I	2235–2252>AATdel 18	1 (1.28)
	L747_A750>P	2238–2248>GCdel 11	2 (2.56)
	L747_A750>P	2239–2248>Cdel 10	1 (1.28)
	L747_T751del	2239–2253del 15	1 (1.28)
	L747_T751del	2240–2254del 15	1 (1.28)
	L747_S752del	2239–2256del 18	1 (1.28)
	L747_T751>P	2239–2251>Cdel 13	1 (1.28)
	E746_S752>V	2237–2255>Tdel 19	1 (1.28)
20	S768I	2303G>T	1 (1.28)
	V769_D770insASV	2307–2308insGACAACGTG	1 (1.28)
	T790M	2369C>T	1 (1.28)
21	L858R	2573T>G	34 (43.6)
B, KRAS
Exon	Amino acid change	Nucleotide change	Cases, n (%)
2	G12R	34G>C	2 (11.1)
	G12C	34G>T	3 (16.7)
	G12V	35G>T	5 (27.8)
	G12D	35G>A	6 (33.3)
	G13D	38G>A	2 (11.1)

EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma virus.